Transcription
Well, a warm welcome to this talk. Today we want to be looking at the antiviral effects of ivormectin. Now, we've been looking at various effects, potential anti-cancer effects of ivormectin over the past couple of weeks, but here we're looking at the antiviral effects, particularly the SARS Corona virus 2 antiviral effects.
Now, this paper that I'm going to be reporting on today, let me just show you it. Uh here we have it here. randomized double blind is a a pilot randomized placeboc control double blind trial of a single oral dose of ivormectin for postexposure prophylaxis of SARS corona virus 2 and there here's the paper actually quite quite a readable paper from Australia.
Now the interesting thing about this paper is it was the trial for this work began in 2021 it's just been published recently towards the end of 2025. So, all of 2022, all of 2023, all of 2024. What the heck is going on here? Why is it taking so long? Better late than never. Evidence for the antiviral effects of ivormectin is accumulating and and it is there. There's no question about it anymore, especially for the anti-coavid effects.
Now, this study used a single dose. Let me just give you a bit of an introduction first of all actually to see if you want to work want to listen. people who took one small dose of oralmekin after being exposed to the virus. So, a family member, something like that, uh took longer to test positive and had more time alive and free from symptoms. So, we're clearly seeing an antiviral effect. Um multiple reports from in vitro infectious models document ivormectin's antiviral properties. But anyway, specifically in this trial took longer to test positive and had more time alive and free of symptoms. and we'll see why that's indicating antiviral effects. That's what this is about.
Now, this is only giving one single dose after exposure. Now, the doctors we've been talking to recently who use ivormectin to treat COVID, uh these are the 12 mgram tablets. I'll show you them on the overhead. Uh these are the 12 migram tablets that I use uh from time to time. Ivormectin tablets uh 12 mg not telling you what to do of course but these particular ones are from this uh Indian manufacturer here um 12 milligs um but uh we were talking to professor Clansancy for example a few days ago and when he got co of course we're not telling you what to do but when he got co he took two of these 24 milligrams a day for 5 days so two two tablets a day for 5 days um when I was uh trying to get my prostate specific antigen down. Um it's a separate story that one, but I I used 12 milligrams a day for 7 weeks and had no side effects. Given that I've said it, I better tell you briefly what it is now. But my PSA was increased. So I thought, is my PSA increased because I got prostate cancer? Because at my age, that's not improbable. So I took some ivormectin every day for 7 weeks. No side effects at all. PSA didn't go down. And I think that's a possible indicator uh that I didn't have prostate cancer. Not that that's why I believe I didn't have prostate cancer. I had an MRI scan to demonstrate that. But the point is I talk I took one a day for 7 weeks with no side effects. Uh but uh as we say, a lot of doctors are recommending 24 milligrams a day for people with COVID infection and potentially as we'll see with other viral infections. Of course, this is purely for educational purposes, not telling you what to do, but you know that by now.
So, multiple reports from in vitro infectious models document ivormectin's antiviral properties. This is really quite beyond dispute really, and we'll look at some mechanisms if you hang around. Ivin has broad uh spectrum antiviral activity from this paper. So it's not just SARS corona virus 2. It's a broad spectrum of viruses particularly um there's a condition called uh break bone fever or or deni fever which is as the name implies it's agony. It feels like broken bones. Ivormectin is almost certainly effective against that and should be uh large scale trial should be done on this.
Um so this is a randomized double blind placebo control trial. Tick tick tick. That's all good. Um single oral ivamectin dose as a prophylaxis for SARS corona virus 2 very small dose single dose try to evaluate the effect effectiveness of a single low dose of ivormectum and uh as we've seen it is effective in some areas now um very low dose as I've said um if someone was exposed to um if I was exposed to SARS corona virus 2 and want to prevent it I would take a larger dose for a longer period of time but even with this minimum dose really very small dose we're getting an effect indicating a potent anti-sAr corona viral 2 viral activity in my view um ability to prevent SARS corona virus 2 wasn't really know well it is known it is known but this is the the uh the researcher being modest this is what they said they're investigating ability to reduce symptoms of infection did occur. Yes, it does do that according to this study.
Right. The method um asymptomatic community dwelling adults enrolled within 72 hours of a close contact. Now quite a few of these were the tablet was given the momentum was given within 24 hours where you'd expect it to be more effective. So a bit of a delay in some of them not ideal there but still giving useful information. Now uh what dose did they give? Well, they gave a single dose of 200 micrograms per kilogram. So, for example, in a 65 kg woman, that would be 13 milligrams. Remember, these were these ones were 12 mg. So, it' be one of those in a tiny bit, I suppose. Um, 80 kg man, they gave the equivalent of 16 milligrams. So, again, less than the 24 milligrams that would probably uh take if I got it myself.
Today primary outcome was um did people convert to a positive PCR or rapid antigen test within 14 days of close contact. Short answer to that is no it didn't protect against that secondary outcome which they also look for for those who tested positive days alive and free of symptoms 14 and 28 days following ivormectin. Yes, it was effective for that. I'm going to give you some numbers on that just now.
Um now um this is days from close contact until a positive preliminary chain reaction or rapid antigen test. Now the originally recruited 53686 patients met the inclusion criteria. 68 adhered to the protocol and were admitted to the analysis. small numbers you would have got better much better results with larger numbers of course but uh this is uh done in Australia where the mood against um ivormectin was pretty strong so ivormectin arm 11 out of 36 tested positive placebo arm 11 out of 32 tested positive so we see with this small numbers at least we're not getting protection against the virus getting into the person but we are getting other remarkably benefit icial effects which we're going to see now.
Um so Ivamekin did not prevent people testing positive but days from close contact until a positive test were increased by 2.3 days in the ivormectin group. So people were taking much longer to test positive. The probability of that arising by chance was 3.3 out of 100. So that's a significant result. So Ivamectin lengthened the incubation period in indicating it had an antiviral effect and of course also potentially giving time for reinfection. It could have been that a lot of these patients were subject to a second uh antigenic challenge um as they went along. So what this probably means is viral load needed to precipitate clinical disease took longer to develop. So the ivormectin was having an antiviral effect taking it longer for the viral replication to reach the number of viral particles that made people sick indicating an antiviral effect from ivormectin. uh infection may have been prevented from a primary contact indicating antiviral effect as well as we said time for a secondary contact to also infect the person because this was 2021 where there was a lot of uh a lot of co around and this was also the getting into the omocron era as well which of course is incredibly was incredibly infectious days alive and symptom pre-inccreased by 2.5 days in the ivormectin group again unlikely that result would arise by chance it's a significant result. It's less than P=0.05. So I mean delayed the onset of symptoms in people who tested positive longer asymptomatic period again indicating that the virus was being combed.
Now we have to stress that this was with a very low dose. Had they carried on being given 24 milligrams for 2 or 3 days probably most of these people would have got no symptoms at all. they would have had essentially asymptomatic infection. They probably still got infected as we've seen or they may not. We we don't know because we haven't got bigger big enough numbers really to adjudicate that. But it shows in my mind clearly the ivormectum was having a an antiviral effect taking it longer for them to test positive and keeping them healthy for a longer period of time indicating an antiviral effect. had they been given 12 milligrams a day for three or four days as we say probably have an even greater antiviral effect. So um given this one dose these the this is quite a given it's one dose this is an incredible result actually for one one single dose one dose amazing.
Fatigue was never taken up by uh authorities around the world excuse me right uh controls uh controlling included so they took account of age prior SARS corona virus to infection body mass index hypertension lung disease well-conducted study.
Conclusion, we did not demonstrate that a single oral dose of lowd dose ivormectin administered to people within 72 hours of close contact with a case of SARS corona virus 2 prevented infection. So fair enough didn't actually stop them getting infected. But we know of course that this is a disease that initially affects the mucosa. What it did do was stop them pre prevent the disease escalating systemically probably because it's hard to see that anything really would prevent the the infection getting into the respiratory mucosa. Uh anyway with a larger sample it may have done. Of course, we don't know that amongst those who did convert to a positive PCR or rapid antigen test, ivormectin significantly lengthened the time from close contact to conversion, ivormectin increased the number of days alive and free of symptoms, both indicating an antiviral effect. So there we are quite convincing despite a really tiny dose, one single dose. Just think what could have been achieved in terms of life saved if this had been rolled out using a proper therapeutic dose. Quite incredible.
Now, I'm going to give you a few more details now for those that are interested. Um, this uh trial initiated in 2021. So, why the heck did it take so long? Open question. Ivormectum was discovered in 75. Massively used around the world. Over three billion people have had this drug. Won the Nobel Prize in 2015. This is not fringe stuff discovered by Santosia Morrow developed by William Campbell. Very low incidence of serious adverse events. It's one of the world's safest drugs. In fact, the people that did have adverse events from this, what what happened with most cases was they took the ivamein and the ivamectin killed the parasites and the parasites died and the material from inside the parasites got out into the person's systemic circulation all at once. So it was like being injected with dead mushed up parasite which of course would cause would cause adverse events but that's an indication of how effective the the ivormectin was at killing the parasites. We now know it's antiviral. Is it anti-cancer as well? Probably quite amazing these natural drugs because of course this is from a bacterium discovered near a golf course in Japan. They have multiple modalities of action. They work in lots and lots of different ways. They're not like man-made pharmaceuticals that have like one mechanism of action. They affect huge amounts of systems in the body working in multiple ways.
Um so you could put this two ways. God made God made drugs work better than humanmade drugs or you could say depending on your worldview that it's had a long time for evolutionary processes to perfect these molecules. But either way, these drugs have uh these natural drugs very often have multiple modalities of action. Um so virtually no side effects. I had none personally. No incidence, no instance of resistance over 25 years. This can go on serving humanity indefinitely into the future.
Ivormectin can bind to inhibit the nuclear roles of uh host importing a a alpha a alpha protein. Right? That's gobbledegook. So what what what this means is of course is in a cell you have the uh you have the whole cell and inside you have the nucleus. Now material has to get from the cytoplasm into the nucleus especially in a lot of viral infections then from the nucleus back out so that the cell can then make more viral particles which are then exported from the from from the surface of the cell that would be a new virus. Now what these what this means here is ivormectin combined to inhibit the nuclear transport roles of host importing a these proteins if if we imagine let's draw a draw up of the imagine that's the nucleus there in actual fact there's pores in the nuclear membrane like this there's pores in it and there's proteins guard the way in and the way out of air. So, ivamectin will inhibit these basically blocking these up. So, normally the uh viral products will get into the nucleus, trigger their viral replication processes and get out again. But if it's blocked up, they can't and that can work against a range of viruses that need to go into the nucleus as part of their reproductive cycle. So, that's the way one of the ways it's working.
Um, but there's many other possible mechanisms as well because these natural molecules have so many ways that they can work. So this protein that's blocked up here is known to mediate the nuclear import of various viral proteins and key host factors. So it's blocking up the nucleus. Nucleus, of course, is where the chromosomes are. This is where the deoxyribboucleic acid is in the in the chromosomes of the cell and it's stopping it going from the cytool the cytoplasm of the cell into the nucleus and from the nucleus out to the cytoplasm of the cell therefore preventing viral replication. Makes perfect sense actually.
Uh other quite uh distinct antiviral actions of ivormectin have been proposed. um high therapeutic concentrations collecting the lungs stable for 30 days. Now this is research from cattle actually. So what happens is um well what seems to happen here is that the ivamectin can be given in relatively low doses because it goes to the lungs and can be concentrated in the lungs. It can protect particularly against respiratory viral infections. Is it stable in human lungs for 30 days like it is in cattle lungs? We don't know. The studies have never been done. But if it's stable in cattle lungs for cow lungs for for 30 days, I imagine it's stable in human lungs for quite a reasonable period of time as well. And the concentrations that can occur even with small doses are sufficient to have this antiviral effect. That now seems pretty clear from the pharmacco uh the pharmacodnamics is how it works and the pharmacocinetics is how long it will stick around for. So that evidence really is is pretty well there.
Now I would have thought um trial was based on strong clinical retrospective. This is the trial we're talking about. trial was based on the strong clinical retrospective association of statistically significant lower mortality in patients who received oralin just 200 micrograms per kilogram uh compared with the usual care and that's actually the study that stimulated this seems to be this study here from what I can gather and uh it is pretty convincing I'll just briefly tell you some of the outcomes of it Ivormectin patients had 15% mortality in hospitalized patients non ivamectin patients 25.2% mortality so ivamein group way less people dying but in people with severe pulmonary disease the mortality in the ivormectin group was 38.8 8 the mortality in the controls was 80.7 so only under 20% of the control surviving um and many other studies that show similar benefit.
Um let's leave the last word to Dr. Pierre Corey um this is his book here war on ivormectin um he says this it's no longer debate a debatable fact that treating covid with ivormectin leads to a highly statistically significant improvements in time to viral clearance time to clinical recovery hospitalization and death pretty clear really I would have thought but in terms of prevention He also says this up until now I've mostly been talking about treating co treating COVID with ivormectin. I haven't even gotten to its enormous preventative prophylaxis capacities demonstration in 17 clinical trials, four randomized control trials and one propensity match study. 16 of the 17 trials produced not only large magnitude positive impacts but highly statist statistically significant ones as well. I have never in my career Dr. Cory says seen an evidence base this strong for preventing for any preventative therapeutic. So had it been used in the pandemic uh more fully um it could have prevented way more cases than the vaccines ever did and it could have prevented a lot more patients from dying and if we'd gone to English nursing homes and given them ivormectin instead of morphine and mazzylam the fatality of the pandemic due to eratrogenesis. Deaths caused by medical treatment would have been dramatically less in my view. Not for me to tell you what you think. Look at the papers. Look at the evidence. Tell me what you think. I'm convinced.
And we need to know what the properties of ivormectin now are because of its multiple modalities of action against other viral infections and against other diseases such as cancer. In my view, it is unethical if these trials are not done. Don't forget, don't take anything based on what I say. This is just for education. But let me know what you think. That's what the comment section's for. Let's finish there before we get mad at all the unnecessary deaths. But for now, thank you for watching.